Clinical Science
Classification of Strokes in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor
Abstract
BACKGROUND AND OBJECTIVE:
The purpose of this study was to identify the differences in the types of strokes seen in patients receiving intravitreal anti-vascular endothelial growth factor (VEGF) compared with normal control populations.
PATIENTS AND METHODS:
We performed a retrospective consecutive review of all patients receiving intravitreal anti-VEGF injections in Olmsted County, Minnesota, from January 1, 2004, to December 31, 2013, for exudative age-related macular degeneration (AMD), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), or retinal vein occlusion (RVO). A 2-year follow-up period was required for study inclusion. Three age- and sex-matched cohorts were identified.
RESULTS:
A total of 2,541 patients were examined. There were 690 patients identified during the study period as receiving an intravitreal injection for AMD, DME, PDR, or RVO. Of these patients, 38 (5.8%) suffered a stroke after starting intravitreal injection therapy. Of these strokes, 27 (71.1%) were ischemic, six (15.8%) were embolic, and five (13.2%) were hemorrhagic. There were no differences in the types of strokes identified among the patients receiving intravitreal injections between the case cohort and the control cohorts (P > .05 for all).
CONCLUSION:
The authors' data suggest there is no predilection to the development of ischemic infarcts or hemorrhagic strokes in those patients receiving intravitreal anti-VEGF compared with control populations.
[Ophthalmic Surg Lasers Imaging Retina. 2019;50:e140–e157.]
- 1.Mehta S. Age-related macular degeneration. Prim Care. 2015; 42(3):377–391.
10.1016/j.pop.2015.05.009 Crossref Medline, Google Scholar - 2.Ashraf M, Souka AA, Singh RP. Central retinal vein occlusion: Modifying current treatment protocols. Eye (Lond). 2016; 30(4):505–514.
10.1038/eye.2016.10 Crossref Medline, Google Scholar - 3.Bandello F, Cunha-Vaz J, Chong NV, New approaches for the treatment of diabetic macular oedema: Recommendations by an expert panel. Eye (Lond). 2012; 26(4):485–493.
10.1038/eye.2011.337 Crossref Medline, Google Scholar - 4.Brown DM, Kaiser PK, Michels M, ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1432–1444.
10.1056/NEJMoa062655 Crossref Medline, Google Scholar - 5.CATT Research GroupMartin DF, Maguire MG, Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364(20):1897–1908.
10.1056/NEJMoa1102673 Crossref Medline, Google Scholar - 6.Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419–1431.
10.1056/NEJMoa054481 Crossref Medline, Google Scholar - 7.Simó R, Sundstrom JM, Antonetti DA. Ocular anti-VEGF therapy for diabetic retinopathy: The role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care. 2014; 37(4):893–899.
10.2337/dc13-2002 Crossref Medline, Google Scholar - 8.Scappaticci FA, Skillings JR, Holden SN, Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007; 99(16):1232–1239.
10.1093/jnci/djm086 Crossref Medline, Google Scholar - 9.Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis. JAMA. 2011; 305(5):487–494.
10.1001/jama.2011.51 Crossref Medline, Google Scholar - 10.Frizzell JP. Acute stroke: Pathophysiology, diagnosis, and treatment. AACN Clin Issues. 2005; 16(4):421–440; quiz 597–598.
10.1097/00044067-200510000-00002 Crossref Medline, Google Scholar - 11.Easton JD, Saver JL, Albers GW, Definition and evaluation of transient ischemic attack: A scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009; 40(6):2276–2293.
10.1161/STROKEAHA.108.192218 Crossref Medline, Google Scholar - 12.Kurland LT, Molgaard CA. The patient record in epidemiology. Sci Am. 1981; 245(4):54–63.
10.1038/scientificamerican1081-54 Crossref Medline, Google Scholar - 13.Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996; 71(3):266–274.
10.4065/71.3.266 Crossref Medline, Google Scholar - 14.St Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ, Rocca WA. Generalizability of epidemiological findings and public health decisions: An illustration from the Rochester Epidemiology Project. Mayo Clin Proc. 2012; 87(2):151–160.
10.1016/j.mayocp.2011.11.009 Crossref Medline, Google Scholar - 15.Campion ME, Naessens JM, Leibson CL, Shaller D, Ballard DJ. The Olmsted County Benchmark Project: Primary study findings and potential implications for corporate America. Mayo Clin Proc. 1992; 67(1):5–14.
10.1016/S0025-6196(12)60270-5 Crossref Medline, Google Scholar - 16.Campbell RJ, Bell CM, Paterson JM, Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: A time series analysis. Ophthalmology. 2012; 119(8):1604–1608.
10.1016/j.ophtha.2012.05.028 Crossref Medline, Google Scholar - 17.Cleary CA, Sharaznayan D, Hickey-Dwyer M. Intravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke. Ir Med J. 2011; 104(5):146–149. Medline, Google Scholar
- 18.Ng WY, Tan GS, Ong PG, Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2015; 159(3):557–564.e1.
10.1016/j.ajo.2014.12.005 Crossref Medline, Google Scholar - 19.Schlenker MB, Thiruchelvam D, Redelmeier DA. Intravitreal anti-vascular endothelial growth factor treatment and the risk of thromboembolism. Am J Ophthalmol. 2015; 160(3):569–580.e5.
10.1016/j.ajo.2015.06.011 Crossref Medline, Google Scholar - 20.Semeraro F, Morescalchi F, Duse S, Gambicorti E, Romano MR, Costagliola C. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: An overview. Expert Opin Drug Saf. 2014; 13(6):785–802. Medline, Google Scholar
- 21.Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev TANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009; 116(1):57–65.e5.
10.1016/j.ophtha.2008.10.018 Crossref Medline, Google Scholar - 22.Antoszyk AN, Tuomi L, Chung CY, Singh AFOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): Year 2 results. Am J Ophthalmol. 2008; 145(5):862–874.
10.1016/j.ajo.2007.12.029 Crossref Medline, Google Scholar - 23.Singer MA, Awh CC, Sadda S, HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012; 119(6):1175–1183.
10.1016/j.ophtha.2011.12.016 Crossref Medline, Google Scholar - 24.Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang KSEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology. 2013; 120(11):2292–2299.
10.1016/j.ophtha.2013.03.046 Crossref Medline, Google Scholar - 25.Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994; 308(6921):81–106.
10.1136/bmj.308.6921.81 Crossref Medline, Google Scholar - 26.Go AS, Mozaffarian D, Roger VL, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2014 update: A report from the American Heart Association. Circulation. 2014; 129(3):e28–e292. Medline, Google Scholar
- 27.Grady D, Wenger NK, Herrington D, Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000; 132(9):689–696.
10.7326/0003-4819-132-9-200005020-00002 Crossref Medline, Google Scholar - 28.Grysiewicz RA, Thomas K, Pandey DK. Epidemiology of ischemic and hemorrhagic stroke: Incidence, prevalence, mortality, and risk factors. Neurol Clin. 2008; 26(4):871–895, vii.
10.1016/j.ncl.2008.07.003 Crossref Medline, Google Scholar
